- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01354379
Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008 Administered by Sprayer
26 mars 2013 uppdaterad av: NanoBio Corporation
A Phase 1 Randomized, Observer-Blind, Controlled, Safety, Tolerability and Immunogenicity Study of Intranasal NB-1008 in Healthy Adult Volunteers Administered by Nasal Sprayer and Pipette
The purpose of this study is to test the safety and immune response of a new intranasal vaccine against influenza, called NB-1008.
The vaccine is composed of a licensed vaccine that is normally given as an injection, called Fluzone, and an adjuvant (additive that helps a vaccine work better), called W805EC.
In a prior clinical study this vaccine showed promising results in terms of being well tolerated and eliciting mucosal and systemic immune responses after administration by a dropper.
In this study NB-1008 is being administered by dropper as well as a nasal sprayer to determine if the sprayer further enhances the immune response.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
125
Fas
- Fas 1
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Kansas
-
Lenexa, Kansas, Förenta staterna, 66219
- Johnson County Clin-Trials
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 49 år (Vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Male or female.
- Are 18-49 years of age, inclusive.
- If female, must be non-pregnant as confirmed by a negative serum pregnancy test conducted at screening and a negative urine pregnancy test conducted at the site within 24 hours preceding receipt of vaccine.
- Females who are not surgically sterile or at least one year post-menopausal agree to use oral, implantable, transdermal or injectable contraceptive or another reliable form of contraception approved by the Investigator for a minimum of 30 days prior to vaccination and for 3 months following vaccination.
- Healthy, as determined by medical history, physical examination, vital signs, and clinical laboratory examinations.
- Comprehension of the study requirements, expressed availability for the required study period, and ability to attend scheduled visits.
- Has given written informed consent to participate in the study.
Exclusion Criteria:
- Presence of significant acute or chronic, uncontrolled medical or psychiatric illness (institution of new medical or surgical treatment, or a significant dose alteration for uncontrolled symptoms or drug toxicity within 3 months). Subjects with a history of chronic cough, frequent sinus infections, sinusitis, allergic rhinitis, nasal polyps or obstruction, including deviated septum significant enough to obstruct the nasal openings are to be excluded. Subjects with seasonal rhinitis may be included if their 'season' does not occur within 3 months of the vaccination date and they are not currently receiving intranasal steroids.
- Receipt of the 22010-2011 influenza vaccine or the 2009 pandemic H1N1 influenza vaccine.
- Positive serology for HIV-1 or HIV-2, or HCV antibodies.
- Platelet count <150,000/mm3.
- Positive urine drug screen.
- History of aspiration, dysphagia, swallowing disorders, stroke or other neurologic conditions that may predispose the subject to aspiration of test articles into the respiratory tract.
- History of Bell's palsy.
- Cancer or treatment for cancer, within 3 years. Subjects with a history of cancer who are disease-free without treatment for 3 years or more are eligible. Basal cell carcinoma (BCC) or (SCC) are allowed, unless present on or near the nose.
- Impaired immune responsiveness, regardless of cause, including diabetes mellitus.
- Presently receiving or history of receiving any medications or treatments that affects the immune system such as immune globulin, interferon, immunomodulators, cytotoxic drugs or drugs known to be frequently associated with significant major organ toxicity, or systemic corticosteroids (oral or injectable) in the past 6 months.
- Chronic use of inhaled or intranasal sprays including decongestants and corticosteroids.
- Presently a smoker or tobacco user or have a history of smoking or tobacco use within the past year prior to screening.
- Receipt or planned administration of a nonstudy vaccine within 30 days before the study, including licensed influenza vaccines and prior to the Day 60 telephone contact. Immunization on an emergency basis with Tetanus Toxoids Adsorbed for adult use (Td or Tdap) up to 8 days before or at least 8 days after a dose of study vaccine will be allowed. Administration of study vaccine can be delayed if a nonstudy vaccine has been administered and will be given as soon as acceptable, as described above.
- Known allergy to any vaccine component, including eggs, egg products, or thimerosal.
- History of allergic and/or anaphylactic type reaction to injected vaccines or to any of the components of NB-1008 [soybean oil, dehydrated alcohol (anhydrous ethanol), polysorbate (Tween 80) and cetylpyridinium chloride (CPC)].
- History of drug or chemical abuse in the year before the study.
- Receipt of any investigational product or nonregistered drug within the 30 days before study entry or currently enrolled in any investigational drug study or intends to enroll in such a study within the ensuing 6 month period.
- Use of nasally administered prescription or over-the-counter (OTC) medications within 7 days before vaccination
- Receipt of blood or blood products 8 weeks before study entry or planned administration prior to the Day 60 telephone contact.
- Donation of blood or blood products within 8 weeks before study entry or at any time up to the Day 28 clinic visit.
- Acute disease within a week prior to vaccination, defined as the presence of a moderate or severe illness (as determined by the investigator through medical history and physical examination) with or without fever. For subjects with a minor illness, such as diarrhea, or mild upper respiratory tract infection with or without low-grade febrile illness, the subject can be re-screened once they have complexly recovered.
- Any condition that, in the opinion of the investigator, might interfere with study objectives.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Fluzone 15 mcg HA 200 mcl IN by Pipette
|
The active control is Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA).
|
Experimentell: NB-1008 15 mcg HA 20% W805EC 200 mcl IN by Pipette
|
NB-1008 is composed of Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA) and 20% W805EC adjuvant.
|
Aktiv komparator: Fluzone 15 mcg HA 200 mcl IN by Nasal Spray
|
The active control is Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA).
|
Experimentell: NB-1008 15 mcg HA 20% W805EC 200 mcl IN by Nasal Spray
|
NB-1008 is composed of Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA) and 20% W805EC adjuvant.
|
Experimentell: NB-1008 15 mcg HA 20% W805EC 400 mcl IN by Nasal Spray
|
NB-1008 is composed of Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA) and 20% W805EC adjuvant.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Safety and Tolerability
Tidsram: 365 Days
|
Number of Participants with Adverse Events (AE) collected through Day 28 and Serious Adverse Events (SAE) collected through Day 365.
|
365 Days
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Systemic Humoral Immune Response
Tidsram: Day 28 and Day 60
|
Serum hemagglutination-inhibition (HAI) Geometric Mean Titer (GMT) and proportion of Volunteers with >=4 fold increase in titer as well as proportion of volunteers with titer >= protective level of 40
|
Day 28 and Day 60
|
Systemic Cell Mediated Immune Response
Tidsram: Day 28
|
Stimulation Index (SI) of antigen-specific proliferation and cytokine secretion of peripheral mononuclear cells (PBMC)
|
Day 28
|
Mucosal Immune Response
Tidsram: Day 14 and Day 28
|
Nasal wash anti-Fluzone IgA Geometric Mean Titer (GMT) and proportion of volunteers with >=4 fold increase in GMT anti-Fluuzone IgA titer
|
Day 14 and Day 28
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Huvudutredare: Casey T Johnson, DO, Johnson County Clin-Trials
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 maj 2011
Primärt slutförande (Faktisk)
1 juni 2012
Avslutad studie (Faktisk)
1 juli 2012
Studieregistreringsdatum
Först inskickad
13 maj 2011
Först inskickad som uppfyllde QC-kriterierna
13 maj 2011
Första postat (Uppskatta)
16 maj 2011
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
28 mars 2013
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
26 mars 2013
Senast verifierad
1 mars 2013
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- NB-1008-002
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
produkt tillverkad i och exporterad från U.S.A.
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Friska vuxna volontärer
-
University of MiamiJames and Esther King Biomedical Research ProgramAvslutadHealthy Lifetime Icke-rökareFörenta staterna
-
University of LeicesterNational Institute for Health Research, United KingdomAvslutadPatienter med hjärtsvikt och konserverad ejektionsfraktion - HFpEF | Patienter med hjärtsvikt med reducerad ejektionsfraktion - HFrEF | Healthy Controls Group - ålders- och könsmatchad
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Grenoble Institut des NeurosciencesAvslutadParkinsons sjukdom | Healthy Controls Group - ålders- och könsmatchadFrankrike
-
Rochester Center for Behavioral MedicineShireAvslutadAdult Attention-Deficit Hyperactivity DisorderFörenta staterna
-
NYU Langone HealthCorium, Inc.RekryteringVaraktighet och effekt av Azstarys på vuxna ADHD-symtom och verkställande funktion tidigt på kvällenAdult Attention Deficit Hyperactivity DisorderFörenta staterna
-
Universität des SaarlandesAvslutadAdult Attention Deficit Hyperactivity DisorderTyskland
-
SunovionAvslutadAdult Attention Deficit Hyperactivity DisorderFörenta staterna
-
SunovionAvslutadAdult Attention Deficit Hyperactivity DisorderFörenta staterna
-
Otsuka Pharmaceutical Development & Commercialization...AvslutadAdult Attention Deficit Hyperactivity DisorderFörenta staterna
-
Gaia AGUniversity Hospital, Saarland; Zentrum für Integrative Psychiatrie KielAktiv, inte rekryterandeAdult Attention Deficit Hyperactivity DisorderTyskland
Kliniska prövningar på Fluzone IN
-
FluGen IncUnited States Department of DefenseAvslutadVaccin mot influensaFörenta staterna
-
St. Jude Children's Research HospitalAvslutadCancer | HIVFörenta staterna
-
Mount Sinai Hospital, CanadaAvslutad
-
PATHVA Puget Sound Health Care System; Seattle Institute for Biomedical and...Avslutad
-
University of RochesterNational Institutes of Health (NIH)Avslutad
-
Bassett HealthcareNew York State Department of HealthAvslutadReumatoid artritFörenta staterna
-
Centers for Disease Control and PreventionKaiser Permanente; Baylor Scott and White Health; Abt AssociatesAvslutadInfluensaFörenta staterna
-
Insight Therapeutics, LLCBrown University; Case Western Reserve UniversityOkänd
-
Sanofi Pasteur, a Sanofi CompanyAvslutadInfluensa | InfluensaFörenta staterna
-
Banner HealthSanofi Pasteur, a Sanofi CompanyOkändKronisk obstruktiv lungsjukdomFörenta staterna